Table 1

Available clinical and mutational data on affected patients and gene carriers of PDB

Pedigree number (sex)
Age at clinical diagnosis or DNA evaluation; present age (years)
AP (U/l)
PDB-related clinical finding
Other relevant clinical data

II-3 (M)a
Deceased
Unknown
Diffuse marked bone deformities (Fig. 2a)
Died at age 76 years from Alzheimer's disease
II-8 (F)a
Deceased
Unknown
Bone deformities at both lower extremities
Died at age 52 years from colon-rectal cancer; also had breast cancer
II-10 (F)a
Deceased
Unknown
Multiple marked diffuse skeletal deformities
Died at age 92 years from unknown cause
III-1 (F)b
57; 65
357
Third lumbar vertebra, pelvis, right proximal femur
Alive
III-3 (F)b
53; 79
560
Pelvis, both tibias
Alive. Apparently healthy
III-5 (M)a
Not assessed
Unknown
Diffuse bone pain
Died at age 80 years from unknown cause
III-6 (F)a
62; deceased
2,259
Right pelvis and proximal femur, IV and VIII left ribs
Died 12 years previously from osteogenic sarcoma on Pagetic bone (right pelvis)
III-12 (M)b
64; 82
380
Left hipc
Alive. Benign prostate hyperplasia
III-13 (M)b
65; 83
610
T5, T10 and L4 vertebral bodies, sacrum, right tibia, right femur, right shoulder and collarbone
Alive. Allergy to pollen, hypertensive cardiopathy
IV-1 (F)
41
<120
None
Alive, age 42, healthy
IV-13 (F)
53
<120
None
Alive, hypertension, age 54
IV-14 (F)
41
<120
None
Alive, age 42, lumbar–sacral discal hernia, goitre
IV-15 (M)
47
<120
None
Alive, age 48 allergy to pollen
IV-16 (F)
48
<120
None
Alive, age 49, allergy to pollen

The M404V mutation was ascertained in individuals listed in bold. The highest observed levels of alkaline phosphatase (AP) are reported for each affected subject; the normal range is less than 120 units/l. PDB, Paget's disease of bone.

aIndividuals strongly suspected to be potential PDB patients after careful reconstruction of the familial clinical history. bThese subjects received two treatment courses with oral risedronate (30 mg/day) for 3 months followed by a 112-day follow-up period without treatment [24]; complete normalization of serum AP levels and bone pain remission were observed in all these treated subjects. cTotal bone scintigraphy was not performed on this subject; the skeletal extent of PDB is on the basis of X-ray evaluations.

Falchetti et al. Arthritis Research & Therapy 2005 7:R1289   doi:10.1186/ar1828